The Effect of Baseline NT-pro BNP on Amiodarone Cardioversion Efficacy in Patients With Acute Paroxysmal Atrial Fibrillation
Objective To explore the assessed value of N-terminal pro B-type natriuretic peptide(NT-proBNP)for the efficacy of amiodarone in cardioversion of acute atrial fibrillation(AF).Methods A total of 68 patients diagnosed as AF(non-valvular disease)in the department of emergency,Sanming Second Hospital from February 2019 to July 2022 were included.All patients were given amiodarone reversion treatment after exclusion of contraindications,and were divided into two groups according to the status of reversion after reversion,namely successful cardioversion group(n=57)and failed cardioversion group(n=11).The symptoms and signs(palpitation,chest pain),electrocardiogram(ST segment depression or not),past medical history(diabetes,hypertension,coronary heart disease,etc.),duration of atrial fibrillation and baseline NT-proBNP level were compared between the two groups.The influencing factors of amiodarone relapse effect in AF patients were analyzed by binary logistic regression.Results There was no significant difference in chest pain,diabetes mellitus,coronary heart disease,ST-segment depression,duration of atrial fibrillation and hypertension between the two groups(P>0.05).In the successful cardioversion group,the incidence of palpitation was 28.07%,the level of NT-proBNP was(229.43±7.24)pmol/L.It was better than 63.64%,(679.99±8.67)pmol/L in the failed cardioversion group,and the difference was statistically significant(P<0.05).The presence of palpitations symptoms,NT-proBNP were the main factors affecting the use of amiodarone for conversion in AF patients(P<0.05).Conclusion Amiodarone is safe and effective foe the cardioversion treatment of AF(non-valvular disease)patients.The presence of palpitation symptoms on admission,baseline NT-proBNP level are important factors to predict the success of amiodarone cardioversion.
N-terminal pro B-type natriuretic peptideamiodaroneatrial fibrillationcardioversionnon-valvular diseaseevaluation value
万方数据
维普
